

# Mapping RBE effects at the cellular level: relevance for fractionated proton radiotherapy

Kevin M. Prise

Centre for Cancer Research & Cell Biology, Queen's University Belfast, UK



# Outline of presentation


---

- Radiation quality, dose and RBE for charged particles
- Studies comparing pristine and SOBPs proton beams to set the baseline
  - Cell survival
  - DNA damage/repair
- Understanding clinically relevant treatment protocols at the cellular level

# Background


**Charged particles are being increasingly used in cancer treatment**  
**By the end of 2015, 154,097 patients had been treated, 131,134 with protons**

- Inverse energy deposition
  - Elevated RBE for cell killing
- ➔ Selective dose localization  
Improved tumour control




- The Bragg curve represents only the physical dose
  - Primary and secondary particles effects
  - Biological effects

# RBE: Relative Biological Effectiveness



**RBE critically depends on both physical and biological parameters:**

- Dose & Dose Rate
- Cell line radiosensitivity
- Ion mass
- Ion energy
- SOBP shape/size




**Currently fixed RBE values are used clinically and disregard any physical and biological dependency potentially limiting particle therapy effectiveness.**

- Dose accuracy required in radiation therapy = 3.5 %
- Any uncertainty on the RBE will translate in the same uncertainty for biological effective dose

# Proton RBEs

- A **range of RBE values** *in vitro* and *in vivo* have been reported
- Average value at mid-SOBP over all dose levels of 1.2, **ranging from 0.9 to 2.1.**
- Studies using **human cells** show significantly **lower RBE** values compared with other cells owing to higher  $\alpha/\beta$  ratios.
- The average RBE value at mid-SOBP **in vivo** is 1.1, ranging from **0.7 to 1.6.**
- The majority of RBE experiments have used ***in vitro* systems and V79 cells with a low  $\alpha/\beta$  ratio,** whereas most of the ***in vivo*** studies were performed in **early-reacting tissues with a high  $\alpha/\beta$  ratio.**
- A value of **1.1 is used clinically**



**Figure 1** Experimental proton relative biological effectiveness (RBE) values (relative to  $^{60}\text{Co}$ ) as a function of dose/fraction for cell inactivation measured *in vitro* (open circles) and *in vivo* (closed circles). The thick dashed line illustrates an RBE of 1.1. Data taken from Paganetti et al.<sup>15</sup>

# Proton RBEs


- Paganetti, H., 2014, *Phys Med Biol* **59**, R419-R452
- 367 datapoints from 100 publications
- Considerable uncertainty but increasing RBE with LET
- Friedrich *et al* 2013, *J Radiat Res* **54**, 494 online database

**Table 1.** Average RBE values based on the data shown in figure 8 considering all  $(\alpha/\beta)_x$ .  $LET_d$  values are given relative to the reference photon radiation. Uncertainties are based on 95% confidence intervals.


	Average RBE (2 Gy)	Average RBE (2 Gy); weights=1	Average RBE (6 Gy)	Average RBE (6 Gy); weights=1
$LET_d = \text{photon } LET_d$ (from linear fit with $LET_d \leq 15 \text{ keV } \mu\text{m}^{-1}$ )	1.02 (0.98, 1.06)	1.08 (1.02, 1.14)	0.99 (0.97, 1.02)	1.08 (1.03, 1.13)
$2 < LET_d < 3 \text{ keV } \mu\text{m}^{-1}$	1.12 (1.07, 1.16)	1.18 (1.13, 1.24)	1.09 (1.07, 1.12)	1.15 (1.11, 1.19)
$LET_d < 3 \text{ keV } \mu\text{m}^{-1}$	1.10 (1.07, 1.13)	1.15 (1.11, 1.19)	1.06 (1.04, 1.08)	1.13 (1.10, 1.15)
$3 \leq LET_d < 6 \text{ keV } \mu\text{m}^{-1}$	1.21 (1.16, 1.26)	1.38 (1.28, 1.49)	1.14 (1.11, 1.18)	1.33 (1.24, 1.41)
$6 \leq LET_d < 9 \text{ keV } \mu\text{m}^{-1}$	1.35 (1.25, 1.44)	1.38 (1.21, 1.55)	1.27 (1.19, 1.35)	1.36 (1.18, 1.54)
$9 \leq LET_d \leq 15 \text{ keV } \mu\text{m}^{-1}$	1.72 (1.54, 1.89)	1.74 (1.53, 1.95)	1.60 (1.36, 1.84)	1.53 (1.34, 1.72)

# Dose, LET and RBE


- Cellular response is determined by the level and **quality of DNA damage**, which reflects the energy deposition pattern.



X-rays



54 keV/μm Si ions



174 keV/μm Fe ions

- Severity of DNA damage** depends on lesion proximity and repairability, hence **it is not a constant value** but depends on physical (particle type, LET, dose) and biological (cell type, oxygenation status, repair capacity) parameters.
- RBE varies with the particle energy and the change of the beam composition (SOBP and nuclear fragmentations): its distribution is **not homogenous** across a treatment field.
- Estimates of the RBE of each specific irradiation scenario and position along the ion path could be important inputs for the development of radiation treatment plans**

# Overall aim




---

**Combined** assessment of **early and late** cellular response including **DNA damage** in a **range of relevant cell lines** to provide systematic high resolution information to develop a rigorous theory of ion radiation action at the cellular and molecular level.

- How does DNA damage and cell response vary across a pristine Bragg curve?
- How biological effectiveness of a pristine curve relates to a Spread Out Bragg Curve?
- What is the contribution of radial dose to heavy ion track structure?
- What other biological parameters play a role?




# INFN Catania




Catana Proton Therapy Facility



# Irradiation Setup – INFN Catania



	P1	P2	P3	P4	P5	P6
Depth water [ mm ]	1.38	20.23	24.59	27.69	29.48	30.08
LET [keV/μm]	1.2	2.6	4.5	13.4	21.7	25.9




	P1	P2	P3	P4	P5	P6
Depth water [ mm ]	1.38	27.42	29.21	29.8	30.7	31.29
LET [keV/μm]	1.11	4.0	7.0	11.9	18.0	22.6




**50 μm positioning accuracy achieved by combining relative dosimetry (Gafchromic films) and secondary standard dosimetry (Markus Chamber)**

# Geant4 Simulation



CATANA  
Beamline –  
INFN, Catania





- Not all quantities measurable experimentally *e.g. LET*.
- The *Geant4* simulation toolkit allows us to model the experimental beam line to predict particle behaviour using the probability sampling *Monte Carlo* method.



**Top:** Geant4 Depth - Dose distribution.  
**Bottom:** Geant4 Depth - LET distribution.




# Survival data



**AG01522** normal human fibroblast cell line



**U87-** human primary glioblastoma cell line with epithelial morphology, obtained from a stage four cancer patient



# Curve fitting and RBE Calculations

## Linear quadratic equation

$$SF = e^{-\left(\alpha L + \beta L^2\right)}$$

$$RBE = D_{X\text{-ray}} / D_{\text{Proton}} @ \text{isoeffect}$$


$$RBE = \left( \left( \alpha_x^2 + 4\beta_x D_p (\alpha_p + \beta_p D_p) \right)^{1/2} - \alpha_x \right) / (2\beta_x D_p)$$

Where  $\alpha_x$ ,  $\beta_x$ ,  $\alpha_p$  and  $\beta_p$  are the  $\alpha$  and  $\beta$  parameter from the X-ray and proton exposure and  $D_p$  is the proton dose delivered


X-rays	$\alpha / \text{Gy}^{-1}$	$\beta / \text{Gy}^{-2}$	$\alpha/\beta$
AGO1522B	$0.54 \pm 0.06$	$0.062 \pm 0.02$	8.71
U87	$0.11 \pm 0.03$	$0.060 \pm 0.01$	1.83

# RBE versus Depth





SF=0.5



SF=0.1






SF=0.01




# RBE versus Dose

Monoenergetic beam




# RBE versus LET





# Biological Effective Dose Profile



- A parameterised RBE model has been used
- In tumour region (SOBP) 17% and 18% increase in biological dose for AGO and U87 cells
- Extension of distal region by 130 and 150  $\mu\text{m}$  respectively


# Do DNA damage and repair rates change predictably in clinically relevant ion-beam dose distributions?

---

- What is the relationship between DNA damage/repair and lethality along a SOBP?
- What are the implications of non-targeted effects for particle radiotherapy where high RBE and steep dose patterns are expected?


# Measurement of direct and bystander DNA damage

62 MeV protons INFN Catania and Clatterbridge



# Beam profile – DNA damage studies


- Douglass Cyclotron Clatterbridge Oncology Centre 60 MeV
- Dose, depth and LET profiles for (a) monoenergetic and (b) modulated SOBP proton beams.
- Relative dose across the depth as measured using diode dosimetry is shown using solid lines.
- Dashed line indicate LET values as calculated using the GEANT4 toolkit.




# Proton – DNA damage and repair

- Pristine versus SOBP  
53BP1 1Gy X-rays or 60 MeV protons
- Increased residual damage at pristine peak
- Gradual increase in residual damage along the SOBP

(a)




(b)




# Cell killing and DNA damage

- Comparing foci data with survival RBE data shows an inverse correlation with initial damage
- Good correlation between residual foci and LET/RBE



(a) AGO 30min Direct




(b) AGO 24hrs Direct


# Fluence – DNA damage per track

- Direct proportionality between foci per track and LET
- 24 hour data predict a minimal LET for producing residual foci of 2.5 keV/μm


Foci Per Track [BGC] (30mins)



Foci Per Track Ratio [BGC]



Foci Per Track [BGC] (24hrs)





# DNA damage versus LET – other ions

## Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams

Ivana Dokic<sup>1,2,3,4,\*</sup>, Andrea Mairani<sup>3,5,\*</sup>, Martin Niklas<sup>1,2,3,4</sup>, Ferdinand Zimmermann<sup>1,2,3,4</sup>, Naved Chaudhri<sup>3</sup>, Damir Kronic<sup>6</sup>, Thomas Tessonier<sup>4,7</sup>, Alfredo Ferrari<sup>8</sup>, Katia Parodi<sup>3,7</sup>, Oliver Jäkel<sup>3,9</sup>, Jürgen Debus<sup>1,2,3,4</sup>, Thomas Haberer<sup>3</sup>, Amir Abdollahi<sup>1,2,3,4</sup>

- For protons, helium, carbon and oxygen ions
- Increased yield of residual foci and foci size with LET





# Protons and DNA repair pathway

- A differential DNA damage response to protons versus photons
- Enhanced susceptibility of **HR-deficient** tumour cells to **proton**-irradiation
- increased sensitivity of **photon**-irradiated tumour cells to **NHEJ** inhibitors were demonstrated.

Radiotherapy and Oncology 116 (2015) 374–380



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: [www.thegreenjournal.com](http://www.thegreenjournal.com)




Molecular radiobiology

Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation



Andrea O. Fontana<sup>a</sup>, Marc A. Augsburger<sup>a</sup>, Nicole Grosse<sup>a</sup>, Matthias Guckenberger<sup>a</sup>, Anthony J. Lomax<sup>c</sup>, Alessandro A. Sartori<sup>b</sup>, Martin N. Pruschy<sup>a,\*</sup>

<sup>a</sup> Department of Radiation Oncology, University Hospital Zurich; <sup>b</sup> Institute of Molecular Cancer Research, University of Zurich; and <sup>c</sup> Paul Scherrer Institute, Villigen, Switzerland






# RBE for different cell types

- Variations in proton RBE in 17 human lung cell lines (1.31 – 1.77 in a subset)
- Correlated with defects in the Fanconi anemia/BRCA pathway of DNA repair

## Biology Contribution

### Lung Cancer Cell Line Screen Links Fanconi Anemia/BRCA Pathway Defects to Increased Relative Biological Effectiveness of Proton Radiation

Qi Liu, PhD,\* Priyanjali Ghosh, BA,\* Nicole Magpayo, BS,\*  
 Mauro Testa, PhD,† Shikui Tang, PhD,† Liliana Gheorghiu, MS,\*  
 Peter Biggs, PhD,† Harald Paganetti, PhD,†  
 Jason A. Efstathiou, MD, DPhil,\* Hsiao-Ming Lu, PhD,†  
 Kathryn D. Held, PhD,\* and Henning Willers, MD\*



# Do RBE effect impact on the response to fractionated proton exposures?

---

- What is the relationship between survival and lethality along a SOBP for fractionated exposures?
- What are the implications of RBE for high dose?

# Proton Therapy Center, Prague






# Treatment room






# Prague Proton - uniform exposures







Dose and LET profiles for actively scanned modulated proton beam with maximum energy 219.65 MeV. Vertical lines mark the four cell irradiation positions at the Entrance, Proximal, Centre and Distal positions. Relative dose and GEANT4 derived dose averaged LET values are indicated in dashed and solid black lines respectively.

# Fractionated proton exposures – total dose

- AGO1522 fibroblasts irradiated with X-rays or protons at entrance, proximal, centre or distal positions with either 1, 2 or 3 fractions, 24 hours apart



# Fractionated exposures – dose per fraction




Fits obtained using the Linear Quadratic Model to estimate survival based on repeated acute response.

$$SF = \exp(-\alpha nD - \beta nD^2)$$



# SOBP – Biologically effective dose



- SOBP Biologically Effective Dose (BED) profile comparing analytically obtained BED values (RBE x Physical Dose (Gy)) when delivering a plateau dose of 3.6, 2.4, 1.8 and 0.8 Gy in both acute (solid colour) and fractionated (dashed colour) regimes.
- Fractionation can be seen to further increase this effect in the plateau region, seeing increases of 8.3 – 12.1 % in integral BED over the clinical case in comparison to 4.6 – 10.6 % for the acute delivery of the same doses.




Marshall et al.,(2016) *Int J. Radiation Oncol Biol Phys*, **95**, 70-7.

# Fractionation predictions

- Decreased effectiveness with increased dose per fraction
- For the target area RBE can decrease below 1.1 dependent on  $\alpha/\beta$  ratio





# Lateral Straggling



Using Carbon beams:

- Smaller dose gradient perpendicular to beam path
- High dose delivery near critical organs

# RBE - painting





Gueulette *et al* 2010

- A homogeneous biologically effective dose requires an inhomogeneous physical dose distribution – even for protons

# Optimising Proton Therapy plans

- Optimised plans on the basis of dose/LET/RBE
- Oxygenation is important for protons
- Need to define the impact of fractionation for plan optimisation



# Conclusions

**RBE varies significantly across the Bragg curve with strong dependency on LET, Dose, and Radiosensitivity**

- RBE variation for proton beams **does not significantly extend the range** of the SOBP (compared to fixed RBE = 1.1)
- Fixed RBE of 1.1 for protons **underestimates the dose delivered to the tumour volume**
- **Residual DSB foci** increase along the SOBP
- Different cell models can have different RBE values related to **defects in DNA repair**
- Future combined chemo-radiation studies with protons need to consider RBE effects
- **Biophysical models** need to be optimised for advanced radiotherapies to include clinically relevant exposure scenarios **including fractionation**
- Future treatment planning systems will input **biological parameters** to personalise the delivery of radiotherapy

# Acknowledgements

## CCRCB

- **Pankaj Chaudhary**
- **Thomas Marshal**
- **Stephen McMahon**
- Karl Butterworth

## QUB Physics

- Fred Currell
- Marco Borghesi
- Fiona Hanton

## National Physical Laboratory (NPL)

- **Giuseppe Schettino**



## INFN Catania

- Pablo Cirrone
- Francesco Romano



## University of Naples

- Lorenzo Manti
- Francesca Perozziello



## Clatterbridge Cancer Centre

- Andrzej Kacperek



## Prague Proton Therapy Centre

- Marie Davidkova
- Anna Michaelidesova
- Vladimír Vondráček



## MGH Boston

- Kathryn Held
- Harald Paganetti

